Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.69 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 11/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 8/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.39 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.39 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL4294625 | 1.00 | SLC7A5 (0.69) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL5011502 | 1.00 | SLC7A5 (0.69) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL18249997 | 1.00 | SLC7A5 (0.69) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| D-Leucine SCHEMBL1537398 | 1.00 | SLC7A5 (0.69) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL122270 | 1.00 | SLC7A5 (0.69) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| D-Leucine SCHEMBL1537401 | 1.00 | SLC7A5 (0.69) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL122271 | 1.00 | SLC7A5 (0.69) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL1537204 | 1.00 | SLC7A5 (0.69) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL1537205 | 1.00 | SLC7A5 (0.69) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| D-Leucine SCHEMBL14698277 | 1.00 | SLC7A5 (0.69) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11929171-B2 | Methods for evaluation and treatment of glycemic dysregulation and atherosclerotic cardiovascular disease and applications thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-12 | — | — | US | disclosed |
| US-20220204654-A1 | CYCLODEXTRIN SUPRAMOLECULAR SCAFFOLDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-06-30 | — | — | US | disclosed |
| US-20200227166-A1 | Methods for Evaluation and Treatment of Glycemic Dysregulation and Atherosclerotic Cardiovascular Disease and Applications Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-07-16 | — | — | US | disclosed |
| WO-2016148046-A1 | GASTRIC VOLUME-REDUCING AGENT | 株式会社明治 | 2016-09-22 | — | — | WO | disclosed |
| WO-2015108157-A1 | PROPHYLACTIC OR AMELIORATING AGENT FOR EARLY SATIATION AFTER EATING OR GASTROESOPHAGEAL REFLUX DISEASE | 株式会社明治 | 2015-07-23 | — | — | WO | disclosed |
| US-20100105774-A1 | ANTIDEPRESSANT | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| WO-2000037087-A1 | COMPREHENSIVE DIETARY SUPPLEMENTS | 4 TODAY INC. (US) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204654-A1 | CYCLODEXTRIN SUPRAMOLECULAR SCAFFOLDS AND USES THEREOF | IAPP, GPR119, INSR | SLC7A5 487/4885SLC1A2 2788/4885SLC1A3 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.